Skip to Content

Notice

Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Herbicides and Contaminants (Ranch Hand Advisory Committee); Notice of Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 62448

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Herbicides and Contaminants (Ranch Hand Advisory Committee).

General Function of the Committee: To advise the Secretary of Health and Human Services (Secretary) and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand study by the U.S. Air Force and provide scientific oversight of the Department of Veterans Affairs (VA) Army Chemical Corps Vietnam Veterans Health Study and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the committee is desirable.

Date and Time: The meeting will be held on November 19, 2004, from 8 a.m. to 3 p.m.

Location: Food and Drug Administration, 5630 Fishers Lane, rm. 1066, Rockville, MD.

Contact Person: Leonard Schechtman, National Center for Toxicological Research (HFT-10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6696, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512560. Please call the Information Line for up-to-date information on this meeting.

Agenda: The Air Force will present for review to the Ranch Hand Advisory Committee the following chapters from the ongoing health study: Chapter 18, Endocrine; Chapter 20, Pulmonary; Chapter 11, Neurology; Chapter 13, Gastrointestinal; Chapter 14, Dermatology; Chapter 10, Neoplasia; Chapter 21, Conclusions; and the Executive Summary.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 5, 2004. Oral presentations from the public will be scheduled between approximately 10:20 a.m. and 10:55 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 12, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Leonard Schechtman at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Start Signature

Dated: October 17, 2004.

Sheila Dearybury Walcoff,

Associate Commissioner for External Relations.

End Signature End Preamble

[FR Doc. 04-23856 Filed 10-25-04; 8:45 am]

BILLING CODE 4160-01-S